Clinical significance of programmed cell death-ligand expression in small bowel adenocarcinoma is determined by the tumor microenvironment

Figure 1 Immunohistochemical localization of programmed cell death-ligand 1 and programmed cell death-ligand 2 in small bowel adenocarcinoma. Magnification 400×. A: T-programmed cell death-ligand 1 expression was membranous and cytoplasmic; B: I-programmed cell death-ligand 1 (I-PD-L1) was positive in peritumoral lymphocytes and macrophages; C: The predominant pattern of T-programmed cell death-ligand 2 expression was in the apical membrane; D: I-programmed cell death-ligand 2 expression was positive in peritumoral lymphocytes and macrophages, similar to that of I-PD-L1.